Atlas, F-Prime launch K36 Therapeutics to advance oncology molecule for elusive epigenetic target
After being in stealth for nearly 11 months, a new biotech has made itself known, complete with an influx of cash from some big-name investors.
K36 Therapeutics, an oncology biotech out of Cambridge, MA, emerged from stealth this morning — announcing a long-finished $30M Series A co-led by F-Prime Capital, Atlas Venture and global investment firm Eight Roads Ventures.
K36 CEO Terry Connolly told Endpoints News that the series was actually closed back in February — and is now just being announced. Connolly said that he expects the funding to get K36 through proof-of-concept studies and hopefully push the candidate to the IND phase, which the biotech plans to file by the end of June next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.